Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up

AuthorsBurnham, SC.
Rowe, CC.
Baker, D.
Bush, AI.
Doecke, JD.
Faux, NG.
Laws, SM.
Martins, RN.
Maruff, P.
Macaulay, SL.
Rainey-Smith, S.
Savage, G.
Ames, D.
Masters, CL.
Wilson, W.
Villemagne, VL.
TypeJournal Article (Original Research)
JournalNeurology
PubMed ID27534714
Year of Publication2016
URLhttp://www.ncbi.nlm.nih.gov/pubmed/27534714
DOIhttp://dx.doi.org/10.1212/WNL.0000000000003094
AbstractOBJECTIVE:
We assessed a blood-based signature, which previously demonstrated high accuracy at stratifying individuals with high or low neocortical β-amyloid burden (NAB), to determine whether it could also identify individuals at risk of progression to Alzheimer disease (AD) within 54 months.
METHODS:
We generated the blood-based signature for 585 healthy controls (HCs) and 74 participants with mild cognitive impairment (MCI) from the Australian Imaging, Biomarkers and Lifestyle Study who underwent clinical reclassification (blinded to biomarker findings) at 54-month follow-up. The individuals were split into estimated high and low NAB groups based on a cutoff of 1.5 standardized uptake value ratio. We assessed the predictive accuracy of the high and low NAB groupings based on progression to mild cognitive impairment or AD according to clinical reclassification at 54-month follow-up.
RESULTS:
Twelve percent of HCs with estimated high NAB progressed in comparison to 5% of HCs with estimated low NAB (odds ratio = 2.4). Forty percent of the participants with MCI who had estimated high NAB progressed in comparison to 5% of the participants with MCI who had estimated low NAB (odds ratio = 12.3). These ratios are in line with those reported for Pittsburgh compound B-PET results. Individuals with estimated high NAB had faster rates of memory decline than those with estimated low NAB.
CONCLUSION:
These findings suggest that a simple blood-based signature not only provides estimates of NAB but also predicts cognitive decline and disease progression, identifying individuals at risk of progressing toward AD at the prodromal and preclinical stages.
© 2016 American Academy of Neurology

http://www.ibas.org.au/what-we-do/publications/3872853


< More publications



SHiQ - COSAQSHIQ - COSAQ

Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive...

Notch monitoring in sleepNOTCH MONITORING IN SLEEP

Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...

NTC releases 'world first' heavy vehicle driver fatigue studyNTC RELEASES 'WORLD FIRST' HEAVY VEHICLE DRIVER FATIGUE STUDY

The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) have released the results of what is hailed as a world-first study into heavy vehicle driver fatigue.

AAMRI Election Statement released on 25th March 2019AAMRI ELECTION STATEMENT RELEASED ON 25TH MARCH 2019

AAMRI released its election statement calling on politicians to commit to three main priorities: ensuring the MRFF reaches $20 billion by 2020-21, provide continued strong support for the NHMRC, and develop sustainable and rewarding career pathways.

IBAS Director Anna Burke unveils her portrait at Canberra's Parliament HouseIBAS DIRECTOR ANNA BURKE UNVEILS HER PORTRAIT AT CANBERRA'S PARLIAMENT HOUSE

Anna Burke had barely got into the swing of her speech at the unveiling of her portrait at Canberra's Parliament House when the ringing of bells caused half her audience to hurry away

National study offers hope for breathlessnessNATIONAL STUDY OFFERS HOPE FOR BREATHLESSNESS

A national medication study is aiming to help thousands of Australians who struggle every day with shortness of breath

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Hospital
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate